• July 28, 2021  

    Latest Advances in the Management of Classical Hodgkin Lymphoma: The Era of Novel Therapies Bookmark

    George Lundberg, MD

    This academic review paper from Blood Cancer Journal outlines many recent advances in the treatment of Hodgkin lymphoma, including for the 15-30% of patients who do not respond or relapse after conventional treatment.

    .

  • July 28, 2021  

    New Approvals for Liver Cancer Mark ‘Golden Age’ of Treatment Bookmark

    George Lundberg, MD

    Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

    .

  • July 28, 2021  

    Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma Bookmark

    George Lundberg, MD

    Oncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.

    .

    .

  • July 28, 2021  

    2021 ASCO Annual Meeting Bookmark

    George Lundberg, MD

    Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

    .

  • July 28, 2021  

    FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy Bookmark

    George Lundberg, MD

    On May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.

    .

  • July 28, 2021  

    Advances in Colorectal Cancer Research Bookmark

    George Lundberg, MD

    This outline from the National Cancer Institute covers recent research on colorectal cancer.

    .

  • July 14, 2021  

    What’s New in Melanoma Treatment in 2021?

    Emma Shtivelman, PhD

    I last wrote about melanoma treatment more than 2 years ago, a fairly long time in the evolution of treatments for this type of cancer. Just as a refresher, the current mainstays of drugs to treat melanoma fall into two categories: Immune checkpoint inhibitors (ICI), antibody drugs that bind to proteins found on the immune system’s T cells—namely, PD-1 (which is targeted by the… Read more »

  • June 12, 2021  

    NALIRIFOX Shows Promise in Early Studies Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: NALIRIFOX, a combination of liposomal irinotecan (Onivyde) with fluorouracil (5-FU), leucovorin, and oxaliplatin is shown to be safe as a first line treatment in locally advanced or metastatic pancreatic cancer.

    .

  • June 12, 2021  

    Multi-Site Precision Promise Study Opens Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Learn about Precision Promise, an adaptive multi-site clinical trial spearheaded by the Pancreatic Cancer Action Network.

    .

  • June 12, 2021  

    New Trial to Find Biomarkers to Guide Treatment Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: A new clinical trial is using precision medicine to identify the best individualized standard-of-care options for pancreatic cancer patients.

    .